Eroxon®’s safety and efficacy are clinically proven, as demonstrated in two Phase 3 trials in Europe and the US. These trials provided the basis of the EU CE mark and UKCA mark regulatory approvals, meaning that Eroxon® is approved as a medical device in the EU and UK for the treatment of ED. The trials also formed the foundation of Eroxon®’s regulatory application to the US FDA for marketing authorisation in the US.
The information on this site is intended for consumers and healthcare professionals in the European Economic Area or the United Kingdom. Eroxon is not available in jurisdictions outside the European Economic Area or the United Kingdom. Users outside these jurisdictions,
please click here.